SCHEMBL279709

SCHEMBL279709

Cc1ccc(S(=O)(=O)CNC2CCNCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
SOS1 Q07889 1/20 0.35
EP300 Q09472 1/20 0.34
KDM1A O60341 2/20 0.33
GNAI3 P08754 2/20 0.32
GNAO1 P09471 2/20 0.32
GNAI1 P63096 2/20 0.32
USP2 O75604 1/20 0.32
BRD4 O60885 2/20 0.31
BRD2 P25440 1/20 0.31
BRD3 Q15059 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
MMP13 P45452 1/20 0.30
KIT P10721 1/20 0.30
CREBBP Q92793 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279864 0.69 ALDH1A1 (0.46) KMT2APOLBNPC1RAB9A
SCHEMBL280092 0.64 RAB9A (0.71) KMT2APOLBNPC1RAB9A
SCHEMBL17277494 0.63 ALDH1A1 (0.53) KMT2ASOS1KDM1AGNAI3GNAO1
SCHEMBL6956559 0.61 HTR2C (0.46) KMT2A
SCHEMBL27978656 0.61 HSP90AA1 (0.45) KMT2APOLBBRD4RAB9A
SCHEMBL10535198 0.60 KMT2A (0.48) KMT2APOLBBRD4NPC1RAB9A
SCHEMBL10534763 0.60 KMT2A (0.48) KMT2APOLBBRD4NPC1RAB9A
SCHEMBL279726 0.60 NAMPT (0.46) KMT2APOLBRAB9A
SCHEMBL19259741 0.60 LOX (0.64) KMT2APOLB
SCHEMBL2606680 0.60 KMT2A (0.52) KMT2APOLBBRD4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885POLB 4352/4885SOS1 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.